American Academy of Dermatology (AAD) 2022

Efficacy of spesolimab for the treatment of GPP flares across prespecified patient subgroups in the Effisayil 1 study

Improving the clinical trial experience for patients and investigators through a simulated trial in palmoplantar pustulosis (PPP)

Validation of the generalized pustular psoriasis physician global assessment (GPPGA) scale for assessing severity of GPP

Prevalence, comorbidities, and mortality of generalized pustular psoriasis (GPP): a literature review

Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study

Clinically significant improvements in patient-reported outcomes (PROs) in patients with a generalized pustular psoriasis (GPP) flare treated with spesolimab